HUTCHMED (China) Limited has recently made an announcement about initiating a phase 1 study of HMPL-295, its highly selective oral inhibitor of ERK, which is a downstream component of the RAS-MARK pathway signaling cascade. The stock price moved at $34.56, a 14.30% decrease.
About HUTCHMED (HCM stock) study on ERK inhibitor HMPL-295
HUTCHMED is an innovative commercial-stage, biopharmaceutical company in China. HCM is committed to the global development and commercialization of certain targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HCM initiated its phase 1 study of HMPL-295 to evaluate the safety, tolerability, pharmacokinetics, and preliminary profile of HMPL-295 to determine the maximum tolerated dose and recommended phase 2 dose. HMPL has the tendency to address intrinsic or acquired resistance from upstream mechanisms like RAS, RAF and MEK. The RAS-MAPK pathway is dysregulated in human diseases, particularly cancer, in which mutations or non-genetic events hyper-activate the pathway in more than 50% of cancers. RAS and RAF predict worse clinical prognosis in a wide variety of tumor types, mediate resistance to targeted therapies and immunotherapy. ERK inhibition has the potential to overcome or avoid the acquired resistance from upstream mechanism.
HCM study of ERK oral inhibitor HMPL-295 is the first of the multiple candidates in discovery addressing the RAS-MAPK pathway. We can expect more useful discoveries from the company as there is a lot of room in the RAS-MAPK pathway. However, the reason behind the recent fall in the stock price is yet to be discovered as no new has been published further.